Cargando…

Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy

The natural history of mantle cell lymphoma (MCL) is a continuous process with the vicious cycle of remission and recurrence. Because MCL cells are most vulnerable before their exposure to therapeutic agents, front-line therapy could eliminate MCL cells at the first strike, reduce the chance for sec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Haige, Desai, Aakash, Huang, Shengjian, Jung, Dayoung, Champlin, Richard, Zeng, Dongfeng, Yan, Fangfang, Nomie, Krystle, Romaguera, Jorge, Ahmed, Makhdum, Wang, Michael L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044039/ https://www.ncbi.nlm.nih.gov/pubmed/30005678 http://dx.doi.org/10.1186/s13046-018-0800-9

Ejemplares similares

Smoldering mantle cell lymphoma
por: Ye, Haige, et al.
Publicado: (2017)

Spontaneous regression of mantle cell lymphoma: a report of four cases
por: Ye, Haige, et al.
Publicado: (2018)

NF-κB signaling and its relevance to the treatment of mantle cell lymphoma
por: Balaji, Swathi, et al.
Publicado: (2018)

Gene mutations and actionable genetic lesions in mantle cell lymphoma
por: Ahmed, Makhdum, et al.
Publicado: (2016)

The B cell receptor signaling pathway in mantle cell lymphoma
por: Merolle, Maria I., et al.
Publicado: (2018)

The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma
por: Huang, Shengjian, et al.
Publicado: (2018)

Progress in molecular feature of smoldering mantle cell lymphoma
por: Jiang, Panruo, et al.
Publicado: (2021)

NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells
por: Li, Yangguang, et al.
Publicado: (2017)

Current trials for frontline therapy of mantle cell lymphoma
por: Steiner, Raphael E., et al.
Publicado: (2018)

Dual targeting of PI3K and BCL‐2 overcomes ibrutinib resistance in aggressive mantle cell lymphoma
por: Ye, Haige, et al.
Publicado: (2022)

The Paramount story /
por: Eames, John Douglas

Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma
por: Wang, Jeffrey, et al.
Publicado: (2019)

ALDO-DHF & Paramount
por: ElGuindy, Ahmed M
Publicado: (2013)

Emerging therapies in mantle cell lymphoma
por: Hanel, Walter, et al.
Publicado: (2020)

Advances in the assessment of minimal residual disease in mantle cell lymphoma
por: Jung, Dayoung, et al.
Publicado: (2020)

Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma
por: Jain, Preetesh, et al.
Publicado: (2023)

Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma
por: Ratnasingam, Sumita, et al.
Publicado: (2019)

Novel targeted therapies for mantle cell lymphoma
por: Alinari, Lapo, et al.
Publicado: (2012)

CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
por: Mohty, Razan, et al.
Publicado: (2022)

BAFF receptor antibody for mantle cell lymphoma therapy
por: Zhang, Keman, et al.
Publicado: (2021)

CAR T-Cell therapy for the management of mantle cell lymphoma
por: Huang, Zoufang, et al.
Publicado: (2023)

The Paramount Duty Texas Owes to Her People
por: Daniel, F. E.
Publicado: (1902)

Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma
por: Klener, Pavel
Publicado: (2019)

Systemic Front Line Therapy of Follicular Lymphoma: When, to Whom and How
por: Pavanello, Francesca, et al.
Publicado: (2016)

Partial prostatectomy: technically feasible, but patient selection is paramount
por: Ball, Mark W.
Publicado: (2017)

Efficacy of front‐line immunochemotherapy for transplant‐ineligible mantle cell lymphoma: A network meta‐analysis of randomized controlled trials
por: Jing, Caixia, et al.
Publicado: (2023)

Ill-fitting dentures as primary presentation of mantle cell lymphoma: A case report and literature review of the primary mantle cell lymphomas of the hard palate
por: Dereci, Ömür, et al.
Publicado: (2015)

Acute Appendicitis in a Man Undergoing Therapy for Mantle Cell Lymphoma
por: Linden, Michael, et al.
Publicado: (2012)

Treatment associated Mantle Cell Lymphoma with Cyclophosphamide therapy for Granulomatosis with Polyangiitis
por: Sheehy, Robert, et al.
Publicado: (2015)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?
por: Chau, I, et al.
Publicado: (2003)

Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2022)

His Majesty the Pig: His Paramount Importance in the Great War
Publicado: (1918)

Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment
por: Zhang, Han, et al.
Publicado: (2016)

Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy
por: Girard, Jennifer, et al.
Publicado: (2019)

CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse
por: Vu, Khoan, et al.
Publicado: (2022)

Physician Attitudes towards Pharmacological Cognitive Enhancement: Safety Concerns Are Paramount
por: Banjo, Opeyemi C., et al.
Publicado: (2010)

Psychosocial Aspects of Bruxism: The Most Paramount Factor Influencing Teeth Grinding
por: Wieckiewicz, Mieszko, et al.
Publicado: (2014)

The Long Non-coding RNAs: Paramount Regulators of the NLRP3 Inflammasome
por: Menon, Mridula P., et al.
Publicado: (2020)

Carcinoma bladder and sliding bladder hernia: Unusual association of paramount significance
por: Agrawal, Manav, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fbat4ns7mbnmjrvfn1h8h9lk8k